SEC Form 4 · accession 0001017491-15-000024
SEELOS THERAPEUTICS, INC. · SEEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard W Pascoe
Officer — Chief Executive Officer · Director
Period of report
Jan 29, 2015
Accepted (ET)
Jan 30, 2015 · 4:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001017491
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.43 | Jan 29, 2015 | A | 300,000 | A | — | Jan 28, 2025 | Common Stock | 300,000 | 300,000 | D |
| Stock Option (right to buy)F2 | $1.43 | Jan 29, 2015 | A | 150,000 | A | — | Jan 28, 2025 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1This option shall vest with respect to one-fourth of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years so the option will be fully vested as of 1/29/2019.
- F2The options vest on the achievement of certain clinical development milestones.